尽管制药巨头礼来公司周四发布的收益超出预期,但其股价仍下跌近12%,市值蒸发超900亿美元。分析师认为,这源于市场对诺和诺德与西维斯健康达成优先列名协议的过度反应,该协议将诺和诺德减肥药Wegovy列入处方药目录,而礼来的Zepbound未入选。利恩克合伙公司重申对礼来股票的“跑赢大盘”评级,同时下调目标价至944美元。礼来CEO表示不参与价格战,将依靠创新产品保持竞争力。周五,礼来股价开盘回升逾...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.